Roche, Alnylam's High-Profile RNAi Alliance Moves into a New Phase
This article was originally published in The Pink Sheet Daily
Executive Summary
Pleased with the progress of their 2-year-old relationship, Roche and Alnylam will now collaborate on discovery and development of specific RNAi compounds for select therapeutic areas.
You may also be interested in...
Silence-Intradigm Deal is Only Year-End Noise on Quiet RNAi Front
The only RNAi-focused merger of the year so far weds two minor players trying to build a much-needed drug delivery platform.
Silence-Intradigm Deal is Only Year-End Noise on Quiet RNAi Front
The only RNAi-focused merger of the year so far weds two minor players trying to build a much-needed drug delivery platform.
Alnylam Set To Bring 3rd Program Into Clinic; Continue Progress Of Other Two
Alnylam plans to file an IND at FDA by the end of this year for a drug candidate to treat transthyretin-mediated amyloidosis (ATTR), with a goal of beginning Phase I study early next year, the biotech reported during an investor research and development presentation Nov. 12 (see chart: "1Alnylam's Aggressive Business Development Program Has Yielded Results")